Your browser doesn't support javascript.
loading
Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz, Barrie J; Jeffery, Douglas; Arnason, Barry; Bigley, Kim; Coyle, Patricia; Goodin, Douglas; Kaba, Samer; Kirzinger, Stephen; Lynch, Sharon; Mandler, Raul; Mikol, Daniel; Rammohan, Kottil; Sater, Richard; Sriram, Subramaniam; Thrower, Ben; Boateng, Francis; Jakobs, Peter; Wash, Mary Beth; Bogumil, Timon.
Afiliação
  • Hurwitz BJ; Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. hurwi003@mc.duke.edu
Clin Ther ; 30(6): 1102-12, 2008 Jun.
Article em En | MEDLINE | ID: mdl-18640466
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adjuvantes Imunológicos / Interferon beta / Esclerose Múltipla Recidivante-Remitente Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2008 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adjuvantes Imunológicos / Interferon beta / Esclerose Múltipla Recidivante-Remitente Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2008 Tipo de documento: Article